Integra Holdings

Integra Holdings is a Jerusalem-based investment vehicle operating closely with Hebrew University of Jerusalem, structured to translate the institution’s life sciences research into funded companies. The relationship with Hebrew University is the central feature: Integra has a privileged channel into the university’s biotech, pharma, and medical device research, and that institutional pathway is the most relevant fact for any founder considering an approach. The source data flags the firm with a higher specialty score, reflecting that clear sub-vertical focus.

Stages span Seed, Series A, and Series B, with check sizes between $1 million and $5 million. Sub-verticals are biotech, pharma, and medical devices. The record does not list specific portfolio companies in the source material. Activity is concentrated in Israel.

For founders, the most reliable path in is through Hebrew University research linkage. Teams without an academic tie to the institution will find the entry harder than a typical VC pitch process, since deal flow is structurally weighted toward the university. Healthcare AI founders working on platforms tied to Hebrew University labs, or on therapeutic and diagnostic assets that originated there, are the clearest fit. Pure software AI without a biology, pharma, or device anchor is less likely to match. Founders should plan around the academic licensing and IP structure that comes with university-spinout deals, including milestone royalties and any institutional governance involvement.